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Introduction:
What is the topic?
Malignant 
Hyperthermia 
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Why choose 
Malignant 
Hyperthermia? 
• Anesthesia	providers	and	perioperative	nurses	play	a	pivotal	role	in	the	identification	and	successful	management	of	the	condition	
• For	a	patient	to	survive	a	malignant	hyperthermia	crisis,	prompt	recognition	and	treatment	is	vital	(Mullins,	2018)	
• With	proper	education	and	understanding	of	the	pathophysiology	of	the	disorder,	negative	patient	outcomes	can	be	prevented
• The	understanding	of	MH	is	essential as an	anesthesia	care	provider
• A	20-year-old	male	patient	presented	following	a	motor	vehicle	crash	with	altered	mental		status		and	a	laceration	to	the	parietal	region	of	his	head.
• The	prehospital	care	providers	reported	that		the	patient	was		the	driver	of		a	vehicle	that	struck	a	concrete	guardrail	at		a	high	speed.
• Initial	assessment		revealed	a	GCS	of	10	.	The	decision	was	made	to		intubate	the	patient	based	on	continued		deterioration	of	his	mental	status
• Vitals	signs	during	intubation	were	stable	at	HR	of		82		blood	pressure	152/70,	SpO2	100%,	and	his	temperature	was	not	recorded	prior	to	induction
• Patient	was	preoxygenated	with	a	non-rebreather	mask	and	high-flow	nasal	cannula	and		given	1.5	mg/kg	of	both	ketamine	and	succinylcholine	
• After	administration	of	the	succinylcholine,	the	patient		experienced	prolonged	muscle		fasciculations	of	his	pectoral	and	abdominal		muscles,	and	then	desaturated	to		60%	despite	ongoing	oxygenation	with	a		nonrebreather	mask	and	nasal	cannula
• The	patient’s	glottic	opening	was	easily		visualized	with	a	video	laryngoscope,	and	his	vocal	cords	continued	to	abduct/adduct.	
• The	emergency	medicine	resident	was	able	to	pass	the	tube	successfully	on	the	first		attempt.
• The	patient	was	then	placed	on		continuous	waveform	capnography,	and	the	end-tidal	CO2		(EtCO2)		was	71	mmHg.	
• The	patient		also	became	tachycardic	within	2	min	of	induction,	with	a	heart	rate	noted	in	the	150–160	range.
• The		treatment		team	initially	felt	the	patient	was	inadequately	sedated	and	administered		midazolam	and	fentanyl
• Despite	providing		adequate	ventilation	and	sedation,	the		patient	remained	hypercapnic	and	tachycardic,	with	his	EtCO2		ranging	from	50	to	70	mmHg		and	heart	rate	140–160
• The	team	suspected	MH	at		this		stage	and	activated	the	MH	protocol.	The		protocol,	prompts	a	pharmacist		to	respond	to	the	patient		location	with	dantrolene	(Ryanodex)	and	cooling	agents		in	a	designated	cart.
• The	patient’s	CAT	scan		showed	spinous	process	fractures	and		rib	fractures;	there	were	no	other	injuries	and		no	intracranial	abnormality	noted.
• Bedside		point-of-care	chemistry	revealed	a	potassium	of		3.7,creatinine	of	1.9,	venous	pH	of	7.19,	PCO2		of	65	and	bicarbonate	of		25
• The	patient	was		administered	2.5	mg/kg	of	dantrolene.	His	temperature	at	this	time	was	37.1◦C	(98.8◦F)	
• Patient	was		admitted	to	the	trauma	intensive	care	unit	and		progressed	to	extubation	within	36	hr.	postinjury
• The	patient	continued	to	receive		additional	doses	of	dantrolene	(Ryanodex)	250	mg		every	6	hr.	for	24	hr.
• He	was	discharged	on	Day		7postinjury.	Patient	was	neurologically	intact	and		scheduled	to	follow	up	for	his	orthopedic	injuries(Luckey-Smith & High, 2018)
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Pathophysiological Processes 
Normal 
Physiology 
• In	a	normal	muscle	contraction,	an		action	potential	causes	membrane	depolarization	which	releases	calcium		from	the	sarcoplasmic	reticulum	(SR).	
• The	calcium	moves	into	the	sarcoplasm	via	the	ryanodine	receptors.	The	receptor	is	a	voltage-gated	ion	channels.	
• The	calcium	interacts	with	the	troponin-tropomyosin	complex.	It	creates	the	cross-bridge	between	actin	and	myosin	and	a	muscle	contraction	occurs.
• At	the	end	of	a	muscle	contraction,	calcium	migrates	back	into	the	sarcoplasmic	reticulum	,	and	another	stimulus	is	needed	to	release	calcium		for	a	muscle	contraction	(	Schneiderbanger	et	al.,	2014).	
Underlying  
Pathophysiology 
• MH		is	a	rare	yet	life	threatening	autosomal	dominant	disorder	(affected	individual	has	one	copy	of	a	mutant	gene	and	one	normal	gene	on	a	pair	of autosomal	chromosomes)	(Nagelhout	&	Elishia,	2018,	p.	773).	
• MH	occurs	because	of	a	a	mutation	on	the	ryanodine	receptor,	which	is	the	major	calcium	release	channel	of	the	sarcoplasm	reticulum	(Nagelhout	&	Elishia,	2018,	p.	774).	
• The	anesthetic	agents	trigger	these	mutations,	and	in	turn,	cause	an	atypical	increase	in	release	of	calcium	from	the	sarcoplasmic	reticulum	of	skeletal	muscle	cells	(Mullins,	2018)
• This	results	in	sustained	muscle	contraction	and	abnormal	muscle	metabolism.		
• The	response	leads	to		hypermetabolic	activity	of		increased	oxygen	consumption,	carbon	dioxide	production,	heat	production,	and	lactic	acidic	build	up.	Results	can	then	lead	to	systemic	acidosis,	hyperkalemia,	and	hyperthermia	(Smith	et.	al,	2018).
Signs and Symptoms
• MH	may	present		anytime		during		general	anesthesia	and	the	early	postoperative	phase						(	Mullins,	2018)
• Early	and	specific	sign	of	MH	is		an		unexplained	rise	in	end-tidal	CO2	levels	with	increased	ventilation.	If	succinylcholine	is	used	,the		rise	in	CO2	may	be	more	rapid	(Smith,	et	al,	2018)
• Other	symptoms	include,	tachycardia	and	dysrhythmia,	abrupt	rise	in	core	body	temperature,	generalized		skeletal	muscle	rigidity	and	rhabdomyolysis	(	Smith	et.	al,	2018)
• Progression	of		the	crisis	leads	to	respiratory	and	metabolic	acidosis,	increased	serum	potassium,	elevated	creatine	kinase		levels,	and	myoglobinuria	may		occur.	The		patient	may	also	suffer	from	acute	renal		failure	and/or	disseminated	intravascular	coagulation	(	Smith	et.	al,	2018)	
• The	severity	of	a	MH	crisis	depends	on	how	quickly	the	disease	process	is	suspected	and	how	rapidly	an	appropriate	treatment	is	initiated	(	Schneiderbanger	et	al.,	2014).
• Nurses	should	coordinate	staff	efforts	toward	three	priorities:	dantrolene	preparation,	cooling	the	patient,	and	preparing	for	transport.
• Priority	of	treatment	begins		by	hyperventilating	the	patient	with	100%	oxygen	and	administering	a	dose	of	dantrolene	sodium.
• Dantrolene	is	a	skeletal	muscle	relaxant	that	depresses	muscle	contraction	by	decreasing	intracellular	calcium	concentration	(National	Institute	s	of	Health,	2018).	
Implications for 
nursing care
• The	prevalence	of	MH	is	estimated	at	1:100,000	administered	anesthetics,	but	this	is	likely	underreported.	(	Borth,	2019)
• Half	of	the	patients	diagnosed	with	MH	have	received	a	prior	anesthetic	without	manifesting	MH.	(	Borth,	2019)
• Without	treatment,	the	mortality	rate	for	an	acute	MH	episode	is	as	high	as	80% (	Borth,	2019)
• Complications	increase	3X	per	every	2°C	increase	in	temperature	and	1.6	X	per	30-minute	delay	in	dantrolene	administration	(	Borth,	2019)
• All	staff	members	involved	in	the	care	of	patients	receiving	MH-triggering	agents	should	receive	annual	education	on	MH	treatment	(	Borth,	2019)
• Although	MH	is	a	rare	medical	emergency,	it	is	vital	that	clinicians	and	patients	are	prepared	and	educated	for	the	surgical	procedure	and	the	risk	for	complications	with	a	detailed	plan	in	place	
Conclusion
Implications
for nursing 
care cont.
• Once		stabilized,	patient	should	be	prepared	to	go	to	the	ICU	(	Borth,	2019)	à
§ decreased	heart	rate
§ decreased	end-tidal	carbon	dioxide	(EtCO2)
§ resolution	of	hyperkalemia
• Regular	MH	drills	should	be	performed	to	demonstrate	that	staff	can	mobilize	MH	supplies	(Borth,	2019)
• It	is	required	that		anesthesia	staff	along	with	the	registered	nurses	working	in	the	PACU	must	know	the	response	plan	for	an	MH	event	(Borth,	2019)
•
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